CN1168098A - 3,4-二苯基苯并二氢吡喃在生产用于治疗或预防高脂蛋白血症、高甘油三酯血症、高脂血症或高胆固醇血症或动脉硬化或用于抗凝治疗的药物组合物中的用途 - Google Patents

3,4-二苯基苯并二氢吡喃在生产用于治疗或预防高脂蛋白血症、高甘油三酯血症、高脂血症或高胆固醇血症或动脉硬化或用于抗凝治疗的药物组合物中的用途 Download PDF

Info

Publication number
CN1168098A
CN1168098A CN96191417A CN96191417A CN1168098A CN 1168098 A CN1168098 A CN 1168098A CN 96191417 A CN96191417 A CN 96191417A CN 96191417 A CN96191417 A CN 96191417A CN 1168098 A CN1168098 A CN 1168098A
Authority
CN
China
Prior art keywords
purposes
prevention
treatment
chemical compound
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96191417A
Other languages
English (en)
Chinese (zh)
Inventor
M·沙尔米
N·克斯加德
S·拜恩
B·H·古德哈默
J·U·维斯
C·E·哈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN1168098A publication Critical patent/CN1168098A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
CN96191417A 1995-01-13 1996-01-10 3,4-二苯基苯并二氢吡喃在生产用于治疗或预防高脂蛋白血症、高甘油三酯血症、高脂血症或高胆固醇血症或动脉硬化或用于抗凝治疗的药物组合物中的用途 Pending CN1168098A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DK4195 1995-01-13
DK0043/95 1995-01-13
DK4395 1995-01-13
DK0041/95 1995-01-13
DK6995 1995-01-20
DK0069/95 1995-01-20
DK0766/95 1995-06-30
DK76795 1995-06-30
DK0767/95 1995-06-30
DK0777/95 1995-06-30
DK76695 1995-06-30
DK77795 1995-06-30

Publications (1)

Publication Number Publication Date
CN1168098A true CN1168098A (zh) 1997-12-17

Family

ID=27545138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96191417A Pending CN1168098A (zh) 1995-01-13 1996-01-10 3,4-二苯基苯并二氢吡喃在生产用于治疗或预防高脂蛋白血症、高甘油三酯血症、高脂血症或高胆固醇血症或动脉硬化或用于抗凝治疗的药物组合物中的用途

Country Status (11)

Country Link
EP (1) EP0804189A1 (cs)
JP (1) JPH10511961A (cs)
CN (1) CN1168098A (cs)
AU (1) AU4329296A (cs)
BR (1) BR9606890A (cs)
CA (1) CA2208859A1 (cs)
CZ (1) CZ212397A3 (cs)
HU (1) HUP9800521A3 (cs)
IL (1) IL116745A (cs)
NO (1) NO973241L (cs)
WO (1) WO1996021443A1 (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU3023999A (en) * 1998-03-20 1999-10-18 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for lowering plasma levels of lp(a) in a human or sub-human primate
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
CA2581316C (en) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
MX368063B (es) 2014-02-07 2019-09-18 Novogen ltd Compuestos de benzopirano funcionalizados y uso de los mismos.
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
JPH10511961A (ja) 1998-11-17
CZ212397A3 (en) 1997-11-12
HUP9800521A2 (hu) 1998-12-28
BR9606890A (pt) 1997-10-28
IL116745A (en) 1999-12-22
HUP9800521A3 (en) 1999-12-28
AU4329296A (en) 1996-07-31
MX9705214A (es) 1997-10-31
IL116745A0 (en) 1996-05-14
EP0804189A1 (en) 1997-11-05
NO973241D0 (no) 1997-07-11
CA2208859A1 (en) 1996-07-18
NO973241L (no) 1997-07-11
WO1996021443A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
KR100263009B1 (ko) 3,4-디아릴크로만을 포함하는 뼈 손실 억제에 유용한 조성물
IE870973L (en) Synergistic combination product
US5726202A (en) Benign prostatic hypertrophy
CN1168098A (zh) 3,4-二苯基苯并二氢吡喃在生产用于治疗或预防高脂蛋白血症、高甘油三酯血症、高脂血症或高胆固醇血症或动脉硬化或用于抗凝治疗的药物组合物中的用途
CN1168096A (zh) 3，4-二苯基苯并二氢吡喃在生产用于治疗或预防妇科疾病的药物组合物中的用途
EP0873122B1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of prostatic carcinoma
CA2241623A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
WO1997025034A1 (en) Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5886021A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
JPH10511960A (ja) 特発性の又は生理学的な女性化乳房の治療又は予防のための医薬製剤の製造のための３，４−ジフェニル・クロマンの使用
JP2002534469A (ja) エストロゲン及びデルタ−ゴナジエン−２１−オール−３，２０−ジオンの使用
KR19980701382A (ko) 고리포단백혈증, 고트리글리세리드혈증, 고지방혈증 또는 고콜레스테롤혈증, 또는 동맥경화증의 치료 또는 예방용 또는 항응고제 치료용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용
MXPA97005214A (en) Use of the 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arterioesclerosis or for anti-treatment
CN1207038A (zh) 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
MXPA97005379A (en) Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad
MXPA97005219A (en) Use of 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment of profilaxis of disorders ginecologi
KR19980701384A (ko) 측발성 또는 생리적 여성형유방의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 사용
WO1999048497A1 (en) USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE
CN1207037A (zh) 西替考马l－对映体在制备治疗或预防乳癌药物组合物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication